Abstract
The human immunodeficiency virus type 1 (HIV-1) is a lentivirus that establishes a persistent, long-term infection in its human host. Like all members of this retroviral subfamily, it completes its replication cycle predominantly by budding from the plasma membrane of the infected cell. The newly formed viral particle contains a core that is composed of two copies of the viral genomic RNA and multiple copies of two precursor polyproteins. During or immediately after budding, the polyproteins are cut into subunmits by a virus-specified protease to yield the mature viral core proteins, which include the matrix, capsid and nucleocapsid proteins as well as the viral protease, reverse transcriptase and integrase enzymes. A mature core is essential for viral infectivity. Elimination of virus protease activity through directed mutation of the protease gene results in production of noninfectious mutant viral particles with immature, unprocessed cores.1 Accordingly, the protease is a suitable target for the development of antiviral agents designed to prevent ongoing cycles of the persistent infection.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kohl NE, Emini EA, Schleif WA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA, 1988; 85: 4686–4690.
Toh H, Ono M, Saigo K et al. Retroviral protease-like sequence in the yeast transposon Tyl. Nature, 1985; 315: 691–692.
Pearl LH and Taylor WR A structural model for the retroviral proteases. Nature, 1987; 329: 351–354.
Darke PL, Nutt RF, Brady SF et al. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun., 1988; 156: 297–303.
Kotler M, Katz RA, Danho W et al. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci USA, 1988; 85: 4185–4189.
Lillehoj EP, Salazar FHR, Mervis RI et al. Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol, 1988; 62: 3053–3058.
Huff JR HIV protease: A novel chemotherapeutic target for AIDS. J Med Chem, 1991; 34: 2305–2314.
Vacca JP, Dorsey BD, Schleif WA et al. L-735,524, an orally bioavailable HIV-1 protease inhibitor. Proc Natl Acad.Sci USA., 1994; 91: 4096–4100.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Emini, E.A., Schleif, W.A., Deutsch, P., Condra, J.H. (1996). In Vivo Selection of HIV-1 Variants with Reduced Susceptibility to the Protease Inhibitor L-735,524 and Related Compounds. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_30
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9209-6_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9211-9
Online ISBN: 978-1-4757-9209-6
eBook Packages: Springer Book Archive